Millipore Sigma Vibrant Logo

530197 CD45 Inhibitor VI - CAS 130089-98-4 - Calbiochem

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
130089-98-4C₁₈H₁₂ClNO₃

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
5.30197.0001CN
Retrieving availability...
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable chloronaphthoquinone compound that potently inhibits CD45/PTPRC tyrosine phosphatase activity (IC50 = 290 nM) in a non-substrate-competitive and irreversible manner via targeting an allosteric pocket at the D1-D2 domains interface. Exhibits good selectivity over MKPX, PRL-2, PTP1B/PTPN1, TC-PTP/PTPN2, SHP-1/PTPN6, PEP/PTPN22, LAR/PTPRF, and PTP-Sigma/PTPRS (IC50 >40 µM). Shown to reduce T cell receptor-mediated activation of Lck, Zap-70, MAPK, and IL-2 production in primary T cells and effectively block human Lck pY-394 dephosphorylation in Jurkat, but not CD45-deficient J45.01 line, reducing cellular metabolic activity without affecting viability. Displays immunosuppressive properties against footpad swelling in a murine modle of delayed type hypersensitivity among C57/BL6 mice even when administered (3 mg/kg, i.p) after early onset of inflammation. However, it does not clear existing edema when applied to mice with fully developed inflammation.
      Catalogue Number530197
      Brand Family Calbiochem®
      Synonyms2-(4-Acetylanilino)-3-chloronaphthoquinone, Compound 211, Protein Tyrosine Phosphatase CD45 Inhibitor VI, PTP Inhibitor XXXII
      References
      ReferencesPerron, M., et al. 2014. Mol. Pharmacol. 85, 553.
      Product Information
      CAS number130089-98-4
      FormOrange powder
      Hill FormulaC₁₈H₁₂ClNO₃
      Chemical formulaC₁₈H₁₂ClNO₃
      ReversibleN
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetCD45
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      5.30197.0001CN 04055977261301

      Documentation

      CD45 Inhibitor VI - CAS 130089-98-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      CD45 Inhibitor VI - CAS 130089-98-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      530197

      References

      Reference overview
      Perron, M., et al. 2014. Mol. Pharmacol. 85, 553.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-June-2014 JSW
      Synonyms2-(4-Acetylanilino)-3-chloronaphthoquinone, Compound 211, Protein Tyrosine Phosphatase CD45 Inhibitor VI, PTP Inhibitor XXXII
      DescriptionA cell-permeable chloronaphthoquinone that potently inhibits CD45/PTPRC tyrosine phosphatase activity (IC50 = 290 nM; substrate = 1 mM pp60-src pY-527 peptide) in a non-substrate-competitive, irreversible, and selective manner via targeting an allosteric pocket at the D1-D2 domains interface away from the substrate-binding/catalytic site, exhibiting little potency toward murine PEST or eight human phosphatases (IC50 > 40 µM against pNPP hydrolysis by MKPX, PRL-2, PTP1B/PTPN1, TC-PTP/PTPN2, SHP-1/PTPN6, PEP/PTPN22, LAR/PTPRF, and PTP-Sigma/PTPRS). Shown to increase human Lck pY394 phosphorylation level in Jurkat cells (by 40% in 24 h; 0.5 µM), but not CD45-deficient J45.01 line. Likewise, drug treatment effectively suppresses induction of Lck pY394, Zap-70 pY319, pErk1/2 phosphorylations and IL-2 release in primary murine splenocyte cultures upon T-cell activation (0.5 µM for 48 h) via TCR cross-linking with concomitant reduced metabolic activity (by MTT assay), but not cell death (by Trypan Blue exclusion). Single intraperitoneal injection (3 mg/kg) administered either 1 h or 3 d post Ovalbumin-/OVA-challenge (1 µg /footpad) among OVA-sensitized mice effectively prevents footpad swelling 6 d post challenge (<0.05 mm vs. >0.3 mm, respectively, with or without treatment) in delayed type hypersensitivity (DTH) tests in vivo. Exhibits no detectable cytotoxicity in KB or HEK293 cultures (0.5 µM for 24 h), while a 50% lymphocytes reduction is reported in mice 24 h post 3 mg/kg i.p. dosage with no other apparent adverse effects.
      FormOrange powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number130089-98-4
      Chemical formulaC₁₈H₁₂ClNO₃
      Purity≥98% by HPLC
      SolubilityDMSO (25 mg/ml). Use only fresh DMSO for reconstitution.
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesPerron, M., et al. 2014. Mol. Pharmacol. 85, 553.